Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 5/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.32 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.31 |
| ▸ | WNT3A | P56704 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL632353 | 0.86 | CYP19A1 (0.41) | CYP19A1KITBRAFNOTUMRXRA | |
| SCHEMBL633171 | 0.84 | CYP19A1 (0.39) | CYP19A1 | |
| SCHEMBL632600 | 0.77 | TAAR1 (0.33) | CYP19A1 | |
| SCHEMBL632483 | 0.76 | DHFR (0.37) | IP6K1 | |
| SCHEMBL8212574 | 0.75 | TAAR1 (0.53) | — | |
| SCHEMBL633242 | 0.74 | TAAR1 (0.35) | GRIN1 | |
| SCHEMBL631732 | 0.73 | TAAR1 (0.39) | NOTUMRXRAIP6K1 | |
| SCHEMBL632707 | 0.73 | ALDH1A1 (0.37) | IP6K1ALDH1A1 | |
| SCHEMBL633295 | 0.73 | IP6K1 (0.33) | IP6K1 | |
| SCHEMBL633347 | 0.73 | PIM1 (0.34) | IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586617-B2 | Aminomethyl-4-imidazoles | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2076497-B1 | AMINOMETHYL-4-IMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-2076497-A1 | AMINOMETHYL-4-IMIDAZOLES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-22 | — | — | US | disclosed |
| WO-2008046757-A1 | AMINOMETHYL-4-IMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119535-A1 | AMINOMETHYL-4-IMIDAZOLES | INMT, HTR4, MC4R | CYP19A1 237/4885KIT 4506/4885BRAF 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.